Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection

Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Dousa, Khalid M, Babiker, Ahmed, Van Aartsen, Daniel, Shah, Neel, Bonomo, Robert A, Johnson, John L, Skalweit, Marion J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
ID Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065501/
https://www.ncbi.nlm.nih.gov/pubmed/30090839
http://dx.doi.org/10.1093/ofid/ofy168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065501/
https://www.ncbi.nlm.nih.gov/pubmed/30090839
http://dx.doi.org/10.1093/ofid/ofy168

Ejemplares similares